Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S ADR (NQ: GMAB )

21.66 -0.81 (-3.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >
A Closer Look at 10 Analyst Recommendations For Genmab
Via Benzinga
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
From Genmab A/S
Via Business Wire
Preview: Genmab's Earnings
Via Benzinga
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing good growth, while it is not too expensive. 
Via Chartmill
12 Analysts Have This To Say About Genmab
Via Benzinga
NASDAQ:GMAB qualifies as a high growth stock and is consolidating.
GENMAB A/S -SP ADR (NASDAQ:GMAB)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
NASDAQ:GMAB is an undervalued gem with solid fundamentals.
Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
NASDAQ:GMAB, a growth stock which is not overvalued.
NASDAQ:GMAB is showing good growth, while it is not too expensive. 
Via Chartmill
Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying.
GENMAB A/S -SP ADR (NASDAQ:GMAB) is an undervalued gem with solid fundamentals. 
Via Chartmill
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
From Genmab A/S
Via Business Wire
Expert Ratings For Genmab
Via Benzinga
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
GENMAB A/S -SP ADR (NASDAQ:GMAB) is not too expensive for the growth it is showing. 
Via Chartmill
Decoding 10 Analyst Evaluations For Genmab
Via Benzinga
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Genmab Announces Changes to its Executive Committee
From Genmab A/S
Via Business Wire
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
What 8 Analyst Ratings Have To Say About Genmab
Via Benzinga
What 8 Analyst Ratings Have To Say About Genmab
Via Benzinga
On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
Via Benzinga
GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024
GMAB stock results show that Genmab missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology... 
Via Benzinga
Exposures COVID-19
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. 
Via Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably. 
Via Chartmill
NASDAQ:GMAB, an undervalued stock with good fundamentals.
GENMAB A/S -SP ADR (NASDAQ:GMAB) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.